- Email: [email protected]
Bios
Michael A. Morse, M.D., M.H.S., is Assistant Professor of Medicine at Duke University Medical Center. He received his medical degree from Yale University School of Medicine, and completed internship and residency in internal medicine at The University of Washington, and a Hematology/ Oncology fellowship at Duke University Medical Center. He is the Clinical Trials Director for the Program in Molecular Therapeutics. His research interests include vaccine and T cell therapeutics for malignancies and the treatment of hepatobiliary cancers. H. Kim Lyerly, M.D., is Professor of Surgery at Duke University Medical Center. He received his medical degree from the University of California, Davis, and completed internship, residency, and research fellowship in general surgery at Duke University Medical Center. He is the Director for the Program in Molecular Therapeutics. His research interests include vaccine and T cell therapeutics for malignancies and the treatment of breast cancers. Timothy M. Clay, Ph.D., is Assistant Research Professor of Experimental Surgery at Duke University Medical Center. He received his Ph.D. degree from Bristol Polytechnic, U.K., and completed a postdoctoral research fellowship in the Surgery Branch of the National Cancer Institute. Dr. Clay is the Laboratory Research Director for the Program in Molecular Therapeutics at Duke University Medical Center. His research interests include molecular immunology, immunotherapy, and gene therapy research, with the ultimate goal being the development of new therapies for cancer and viral diseases. Omar Abdel-Wahab, B.S., is currently a third year medical student at Duke University. He received his undergraduate degree from Duke University. He is currently funded through a Duke University Department of Surgery Research Training Fellowship to explore novel systemic and regional therapies for melanoma.
Curr Probl Surg, January 2004
11
Stephen Y. Chui, M.D., is a Fellow in the Division of Hematology/Oncology, Department of Medicine at Duke University Medical Center. He received his medical degree from the Duke University School of Medicine, and subsequently completed internship and residency training in internal medicine at Duke University Medical Center.
Jennifer Garst, M.D., is Assistant Professor of Medicine at Duke University Medical Center. She received her medical degree from the Medical College of Georgia, and completed internship and residency in internal medicine at University of Texas, Southwestern, and a medical oncology fellowship at Duke University Medical Center. Her interests include intervention, epidemiology, and treatment of lung cancer and lung cancer as a women’s health issue. She has a special interest in supportive and symptom management in cancer care.
Jared Gollob, M.D., is Associate Professor of Medicine at Duke University, Director of the Biologic Therapy program at Duke University Medical Center, and Chief of Hematology/Oncology at the Durham VA Medical Center. He specializes in the treatment of melanoma and renal cell carcinoma and his research focuses on the application of cytokine-based therapies to these malignancies and the analysis of the cellular and molecular mechanisms underlying the susceptibility or resistance of tumors to immune modulation.
Peter M. Grossi, M.D., is a Resident in Neurosurgery at Duke University. He also received his medical degree from Duke University. His research interest includes immunotherapy for primary and metastatic brain tumors. 12
Curr Probl Surg, January 2004
Matthew Kalady, M.D., is a Senior Surgical Resident at Duke University Medical Center. He received his medical degree from Duke University Medical School. He has recently completed a NRSA funded 2-year immunotherapy fellowship at Duke University. His interests are hepatobiliary cancers, melanoma, and vaccine strategies.
Paul J. Mosca, MD, Ph.D., is Assistant Professor of Surgery at Duke University Medical Center. He received his medical degree and doctorate in biophysics from the University of Virginia School of Medicine. He completed residency in general surgery and a postdoctoral fellowship in cancer immunotherapy at Duke University Medical Center. His research interests include tumor immunotherapy, modulation of human T cell immunity, and the application of proteomics to the study of tumor biology and immunology.
Mark Onaitis, M.D., is a Senior Surgical Resident at Duke University Medical Center. He received his medical degree from Duke University Medical School. He has recently completed a 2 year immunotherapy fellowship at Duke University. His interests are immunotherapy, rectal cancer, and hepatobiliary malignancy. John H. Sampson, M.D., Ph.D., is Assistant Professor of Neurosurgery and Pathology at Duke University Medical Center. He received his medical degrees from the University of Manitoba in Canada and his doctoral degree in pathology (Neuropathology) from Duke University. He has completed residency training in Neurosurgery. His research interest is drug delivery for and adoptive and active immunotherapy of brain tumors.
Hilliard F. Seigler, M.D., is Professor of Surgery at Duke University Medical Center. He received his medical degree and residency training in surgery at the University of North Carolina at Chapel Hill, and served a post-doctoral NIH fellowship at Duke University Medical Center. His research interests include vaccine therapies for melanoma. Curr Probl Surg, January 2004
13
Eric M. Toloza, M.D., Ph.D., is Assistant Professor of Surgery at Duke University Medical Center. He received his medical and graduate degrees from the University of California, Los Angeles (UCLA) School of Medicine, completed his internship and residency in general surgery at the University of California, Irvine Medical Center, and served a surgical oncology research fellowship at UCLA. He went on to complete a cardiothoracic surgery residency at the Texas Heart Institute as well as a Thoracic Surgical Oncology fellowship at the University of Texas M.D. Anderson Cancer Center in Houston. His research interests include gene and vaccine therapy for thoracic malignancies and stem cell therapy for emphysematous lung diseases.
Douglas Tyler, M.D., is Associate Professor of Surgery at Duke University Medical Center. He received his medical degree from Dartmouth Medical School. He completed his surgical residency at Duke University Medical Center and a surgical oncology fellowship at the University of Texas MD Anderson Cancer Center. He is currently Chief of Surgical Oncology at Duke University Medical Center and Chief of the General Surgery Service at the Durham VA Medical Center. His interests include immunotherapy of melanoma and pancreatic cancer as well as neoadjuvant and regional approaches to these malignancies.
Johannes Vieweg, M.D., is Associate Professor of Urology and Immunology at Duke University Medical Center. He received his medical degree from the University of Munich/Germany and completed a residency in urology at Duke University Medical Center. He received fellowship training in urologic oncology at Memorial Sloan Kettering Cancer Center, New York. His research interest centers on the development of immunotherapeutic strategies for the prevention and cure of genitourinary malignancies.
Yiping Yang, M.D., Ph.D., is Assistant Professor of Medicine and Immunology at Duke University Medical Center. He received his MD degree from Zhejiang Medical University and his PhD from the University of Michigan. He completed his internship and residency in internal medicine at the University of Pennsylvania, and completed a medical oncology fellowship at Johns Hopkins University. His research interests include tumor immunology and antigen-defined immunotherapy for EpsteinBarr virus associated malignancies such as Hodgkin’s lymphoma. 14
Curr Probl Surg, January 2004
Curr Probl Surg, January 2004
11
Stephen Y. Chui, M.D., is a Fellow in the Division of Hematology/Oncology, Department of Medicine at Duke University Medical Center. He received his medical degree from the Duke University School of Medicine, and subsequently completed internship and residency training in internal medicine at Duke University Medical Center.
Jennifer Garst, M.D., is Assistant Professor of Medicine at Duke University Medical Center. She received her medical degree from the Medical College of Georgia, and completed internship and residency in internal medicine at University of Texas, Southwestern, and a medical oncology fellowship at Duke University Medical Center. Her interests include intervention, epidemiology, and treatment of lung cancer and lung cancer as a women’s health issue. She has a special interest in supportive and symptom management in cancer care.
Jared Gollob, M.D., is Associate Professor of Medicine at Duke University, Director of the Biologic Therapy program at Duke University Medical Center, and Chief of Hematology/Oncology at the Durham VA Medical Center. He specializes in the treatment of melanoma and renal cell carcinoma and his research focuses on the application of cytokine-based therapies to these malignancies and the analysis of the cellular and molecular mechanisms underlying the susceptibility or resistance of tumors to immune modulation.
Peter M. Grossi, M.D., is a Resident in Neurosurgery at Duke University. He also received his medical degree from Duke University. His research interest includes immunotherapy for primary and metastatic brain tumors. 12
Curr Probl Surg, January 2004
Matthew Kalady, M.D., is a Senior Surgical Resident at Duke University Medical Center. He received his medical degree from Duke University Medical School. He has recently completed a NRSA funded 2-year immunotherapy fellowship at Duke University. His interests are hepatobiliary cancers, melanoma, and vaccine strategies.
Paul J. Mosca, MD, Ph.D., is Assistant Professor of Surgery at Duke University Medical Center. He received his medical degree and doctorate in biophysics from the University of Virginia School of Medicine. He completed residency in general surgery and a postdoctoral fellowship in cancer immunotherapy at Duke University Medical Center. His research interests include tumor immunotherapy, modulation of human T cell immunity, and the application of proteomics to the study of tumor biology and immunology.
Mark Onaitis, M.D., is a Senior Surgical Resident at Duke University Medical Center. He received his medical degree from Duke University Medical School. He has recently completed a 2 year immunotherapy fellowship at Duke University. His interests are immunotherapy, rectal cancer, and hepatobiliary malignancy. John H. Sampson, M.D., Ph.D., is Assistant Professor of Neurosurgery and Pathology at Duke University Medical Center. He received his medical degrees from the University of Manitoba in Canada and his doctoral degree in pathology (Neuropathology) from Duke University. He has completed residency training in Neurosurgery. His research interest is drug delivery for and adoptive and active immunotherapy of brain tumors.
Hilliard F. Seigler, M.D., is Professor of Surgery at Duke University Medical Center. He received his medical degree and residency training in surgery at the University of North Carolina at Chapel Hill, and served a post-doctoral NIH fellowship at Duke University Medical Center. His research interests include vaccine therapies for melanoma. Curr Probl Surg, January 2004
13
Eric M. Toloza, M.D., Ph.D., is Assistant Professor of Surgery at Duke University Medical Center. He received his medical and graduate degrees from the University of California, Los Angeles (UCLA) School of Medicine, completed his internship and residency in general surgery at the University of California, Irvine Medical Center, and served a surgical oncology research fellowship at UCLA. He went on to complete a cardiothoracic surgery residency at the Texas Heart Institute as well as a Thoracic Surgical Oncology fellowship at the University of Texas M.D. Anderson Cancer Center in Houston. His research interests include gene and vaccine therapy for thoracic malignancies and stem cell therapy for emphysematous lung diseases.
Douglas Tyler, M.D., is Associate Professor of Surgery at Duke University Medical Center. He received his medical degree from Dartmouth Medical School. He completed his surgical residency at Duke University Medical Center and a surgical oncology fellowship at the University of Texas MD Anderson Cancer Center. He is currently Chief of Surgical Oncology at Duke University Medical Center and Chief of the General Surgery Service at the Durham VA Medical Center. His interests include immunotherapy of melanoma and pancreatic cancer as well as neoadjuvant and regional approaches to these malignancies.
Johannes Vieweg, M.D., is Associate Professor of Urology and Immunology at Duke University Medical Center. He received his medical degree from the University of Munich/Germany and completed a residency in urology at Duke University Medical Center. He received fellowship training in urologic oncology at Memorial Sloan Kettering Cancer Center, New York. His research interest centers on the development of immunotherapeutic strategies for the prevention and cure of genitourinary malignancies.
Yiping Yang, M.D., Ph.D., is Assistant Professor of Medicine and Immunology at Duke University Medical Center. He received his MD degree from Zhejiang Medical University and his PhD from the University of Michigan. He completed his internship and residency in internal medicine at the University of Pennsylvania, and completed a medical oncology fellowship at Johns Hopkins University. His research interests include tumor immunology and antigen-defined immunotherapy for EpsteinBarr virus associated malignancies such as Hodgkin’s lymphoma. 14
Curr Probl Surg, January 2004